Supplementary Figure 4 from A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors
Authors:
- Geoffrey KuGKGeoffrey Ku
- Lin ShenLSLin Shen
- Farshid DayyaniFDFarshid Dayyani
- Jeremy KratzJKJeremy Kratz
- Xinjun LiangXLXinjun Liang
- Funan LiuFLFunan Liu
- Zhenning WangZWZhenning Wang
- Laura FellerLFLaura Feller
- Eugenia GirdaEGEugenia Girda
- Hongming PanHPHongming Pan
- Sunnie KimSKSunnie Kim
- Yanhong DengYDYanhong Deng
Open Access
- 1 December 2025
- other
- Published by American Association for Cancer Research (AACR)